HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Azizi, F Articles by Sheikholeslami, F Search for Related Content PubMed PubMed Citation Articles by Azizi, F Articles by Sheikholeslami, F

Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine

Endocrine Research Center and the Division of Cardiology, Taleghani Medical Center, Shaheed Beheshti University of Medical Sciences, PO Box 19395-4763, Tehran, I.R. Iran

(Correspondence should be addressed to F Azizi; Email: Azizi{at}erc.ac.ir)

Objective: To investigate the long-term effects of continuous methimazole (MMI) therapy.

Design and methods: Five hundred and four patients over 40 years of age with diffuse toxic goiter were treated with MMI for 18 months. Within one year after discontinuation of MMI, hyperthyroidism recurred in 104 patients. They were randomized into 2 groups for continuous antithyroid and radioiodine treatment. Numbers of occurrences of thyroid dysfunction and total costs of management were assessed during 10 years of follow-up. At the end of the study, 26 patients were still on continuous MMI (group 1), and of 41 radioiodine-treated patients (group 2), 16 were euthyroid and 25 became hypothyroid. Serum thyroid and lipid profiles, bone mineral density, and echocardiography data were obtained.

Results: There was no significant difference in age, sex, duration of symptoms and thyroid function between the two groups. No serious complications occurred in any of the patients. The cost of treatment was lower in group 1 than in group 2. At the end of 10 years, goiter rate was greater and antithyroperoxidase antibody concentration was higher in group 1 than in group 2. Serum cholesterol and low density lipoprotein-cholesterol concentrations were increased in group 2 as compared with group 1; relative risks were 1.8 (1.12–2.95, P < 0.02) and 1.6 (1.09–2.34, P < 0.02) respectively. Bone mineral density and echocardiographic measurements were not different between the two groups.

Conclusion: Long-term continuous treatment of hyperthyroidism with MMI is safe. The complications and the expense of the treatment do not exceed those of radioactive iodine therapy.

This article has been cited by other articles:

				P. Laurberg, G. Wallin, L. Tallstedt, M. Abraham-Nordling, G. Lundell, and O. Torring TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study Eur. J. Endocrinol., January 1, 2008; 158(1): 69 - 75. [Abstract] [Full Text] [PDF]

				A. Toft and T. C Sandeep Radioiodine treatment of hyperthyroidism BMJ, March 10, 2007; 334(7592): 483 - 484. [Full Text] [PDF]

				P. Laurberg Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur. J. Endocrinol., December 1, 2006; 155(6): 783 - 786. [Abstract] [Full Text] [PDF]

				Radioiodine therapy for hyperthyroidism DTB, June 1, 2006; 44(6): 44 - 48. [Abstract] [Full Text] [PDF]

				P. Abraham, A. Avenell, C. M Park, W. A Watson, and J. S Bevan A systematic review of drug therapy for Graves' hyperthyroidism Eur. J. Endocrinol., October 1, 2005; 153(4): 489 - 498. [Abstract] [Full Text] [PDF]